DLL1: A Potential Drug Target and Biomarker (G28514)

Target Name: DLL1

NCBI ID: G28514

DLL1

DLL1: A Potential Drug Target and Biomarker

DLL1 (Drosophila Delta homolog 1) is a gene that has been identified as a potential drug target or biomarker in the context of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique function and expression patterns make it an attractive target for researchers to study and develop new treatments.

The Drosophila model

Drosophila is a small fly that is commonly used in genetic research as a model organism for many diseases, including cancer. The fruit fly offers several advantages as a model organism, including a relatively short lifespan, a high reproductive rate, and a large number of genetic traits that can be studied. One of the most attractive features of Drosophila is its ability to transmit genetic information through the xenoderean system, which allows researchers to study the function of any gene in the fly.

DLL1 was identified as a gene that was expressed in high levels in the tissues of Drosophila, and its function was confirmed through experiments that demonstrated its involvement in various cellular processes, including cell division, migration, and survival. The DLL1 gene was also shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DLL1 as a drug target

DLL1 has been identified as a potential drug target due to its involvement in various cellular processes that are associated with the development and progression of many diseases. One of the most promising aspects of DLL1 is its involvement in the development of cancer. Studies have shown that DLL1 is involved in the regulation of cell division and survival, which are critical processes for cancer development.

In addition to its involvement in cancer, DLL1 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of progressive neurodegeneration . The role of DLL1 in these conditions is not well understood, but its involvement in these processes suggests that it may be a useful target for new treatments.

DLL1 has also been shown to be involved in the regulation of immune responses, which is important for the development and maintenance of autoimmune disorders. These conditions are characterized by the immune system becoming too active or persistent, leading to inflammation and damage to body tissues. The role of DLL1 in the regulation of immune responses suggests that it may be a useful target for new treatments for autoimmune disorders.

DLL1 as a biomarker

In addition to its potential as a drug target, DLL1 has also been shown to be a potential biomarker for several diseases. The DLL1 gene has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurons, and immune cells . This makes it a potential biomarker for cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key advantages of DLL1 as a biomarker is its stability and persistence. Unlike many other biomarkers, which can be affected by factors such as inflammation or cellular stress, DLL1 has been shown to be a stable and persistent gene in the tissues of Drosophila . This stability makes it a promising biomarker for a variety of diseases.

In addition, the expression of DLL1 has been shown to be regulated by several factors, including growth factors, cytokines, and chemokines. This makes it a potential target for drugs that can modulate its expression and activity.

Conclusion

DLL1 is a gene that has been identified as a potential drug target or biomarker in the context of various diseases. Its unique function and expression patterns make it an attractive target for researchers to study and develop new treatments. While more research is needed to fully understand the role of DLL1 in these diseases, its potential as a drug target and biomarker is an exciting area of 鈥嬧?媟esearch.

Protein Name: Delta Like Canonical Notch Ligand 1

Functions: Transmembrane ligand protein of NOTCH1, NOTCH2 and NOTCH3 receptors that binds the extracellular domain (ECD) of Notch receptor in a cis and trans fashion manner (PubMed:11006133). Following transinteraction, ligand cells produce mechanical force that depends of a clathrin-mediated endocytosis, requiring ligand ubiquitination, EPN1 interaction, and actin polymerisation; these events promote Notch receptor extracellular domain (NECD) transendocytosis and triggers Notch signaling through induction of cleavage, hyperphosphorylation, and nuclear accumulation of the intracellular domain of Notch receptors (NICD) (By similarity). Is required for embryonic development and maintenance of adult stem cells in many different tissues and immune systeme; the DLL1-induced Notch signaling is mediated through an intercellular communication that regulates cell lineage, cell specification, cell patterning and morphogenesis through effects on differentiation and proliferation (PubMed:11581320). Plays a role in brain development at different level, namely by regulating neuronal differentiation of neural precursor cells via cell-cell interaction, most likely through the lateral inhibitory system in an endogenous level dependent-manner. During neocortex development, Dll1-Notch signaling transmission is mediated by dynamic interactions between intermediate neurogenic progenitors and radial glia; the cell-cell interactions are mediated via dynamic and transient elongation processes, likely to reactivate/maintain Notch activity in neighboring progenitors, and coordinate progenitor cell division and differentiation across radial and zonal boundaries. During cerebellar development, regulates Bergmann glial monolayer formation and its morphological maturation through a Notch signaling pathway. At the retina and spinal cord level, regulates neurogenesis by preventing the premature differentiation of neural progenitors and also by maintaining progenitors in spinal cord through Notch signaling pathway. Also controls neurogenesis of the neural tube in a progenitor domain-specific fashion along the dorsoventral axis. Maintains quiescence of neural stem cells and plays a role as a fate determinant that segregates asymmetrically to one daughter cell during neural stem cells mitosis, resulting in neuronal differentiation in Dll1-inheriting cell. Plays a role in immune systeme development, namely the development of all T-cells and marginal zone (MZ) B-cells (By similarity). Blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with the characteristics of a T-cell/NK-cell precursor (PubMed:11581320). Also plays a role during muscle development. During early development, inhibits myoblasts differentiation from the medial dermomyotomal lip and later regulates progenitor cell differentiation. Directly modulates cell adhesion and basal lamina formation in satellite cells through Notch signaling. Maintains myogenic progenitors pool by suppressing differentiation through down-regulation of MYOD1 and is required for satellite cell homing and PAX7 expression. During craniofacial and trunk myogenesis suppresses differentiation of cranial mesoderm-derived and somite-derived muscle via MYOD1 regulation but in cranial mesoderm-derived progenitors, is neither required for satellite cell homing nor for PAX7 expression. Also plays a role during pancreatic cell development. During type B pancreatic cell development, may be involved in the initiation of proximodistal patterning in the early pancreatic epithelium. Stimulates multipotent pancreatic progenitor cells proliferation and pancreatic growth by maintaining HES1 expression and PTF1A protein levels. During fetal stages of development, is required to maintain arterial identity and the responsiveness of arterial endothelial cells for VEGFA through regulation of KDR activation and NRP1 expression. Controls sprouting angiogenesis and subsequent vertical branch formation througth regulation on tip cell differentiation. Negatively regulates goblet cell differentiation in intestine and controls secretory fat commitment through lateral inhibition in small intestine. Plays a role during inner ear development; negatively regulates auditory hair cell differentiation. Plays a role during nephron development through Notch signaling pathway. Regulates growth, blood pressure and energy homeostasis (By similarity)

The "DLL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets